AGM on August 03, 2016
Zydus Wellness Ltd has informed BSE that the 22nd Annual General Meeting (AGM) of the Company will be held on August 03, 2016.11-07-2016
AGM on August 03, 2016
Zydus Wellness Ltd has informed BSE that the 22nd Annual General Meeting (AGM) of the Company will be held on August 03, 2016.Board Meeting Intimation for Results & Closure of Trading Window
Zydus Wellness Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on August 02, 2016, inter alia, to consider & approve the unaudited financial results for the quarter ended on June 30, 2016.Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from July 24, 2016 to...Zydus gets FDA nod for diabetes drug
The company today informed in a statement that it has received the nod from the US drug regulator to market the drug in strengths of 60 mg and 120 mgStatement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Zydus Wellness Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.Cut-off Date
Zydus Wellness Ltd has informed BSE that pursuant to Companies [Management and Administration] Amendment Rules, 2015, the Company has fixed July 27, 2016 as the Cut-Off Date for determining the eligibility of the members entitled to vote by electronic means and at the venue of Twenty Second Annual General Meeting scheduled to be held on August 03, 2016 at 10:00 a.m....Shareholding for the Period Ended June 30, 2016
Zydus Wellness Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click hereZydus Wellness steps on gas: plans Everyuth re-launch, eyes buy-outs
Firm is setting up new plant in Sikkim for Rs 35 crore; expected to go onstream within FY17Zydus group inks pact with Eczacibasi to market biotech products
The collaboration agreement involves the import of bio-similars that are currently unavailable in Turkey, especially for the treatment of cancer.Investor Presentation
Zydus Wellness Ltd has submitted to BSE a copy of Investor PresentationZydus gets USFDA nod for phase II clinical trial of Saroglitazar
The company will be allowed to evaluate Saroglitazar in strengths of 1mg, 2mg and 4mg versus placebo